The use of chronic opioid therapy (COT) for chronic non-cancer pain (CNCP) has increased dramatically in the past two decades. There has also been a marked increase in the abuse of prescribed opioids and in accidental opioid overdose. Misuse of prescribed opioids may link these trends, but has thus far only been studied in small clinical samples. We therefore sought to validate an administrative indicator of opioid misuse among large samples of recipients of COT and determine the demographic, clinical, and pharmacological risks associated with possible and probable opioid misuse. A total of 21,685 enrollees in commercial insurance plans and 10,159 in Arkansas Medicaid who had at least 90 days of continuous opioid use 2000-2005 were studied for one year. Criteria were developed for possible and probable opioid misuse using administrative claims data concerning excess days supplied of short-acting and long-acting opioids, opioid prescribers and opioid pharmacies. We estimated possible misuse at 24% of COT recipients in the commercially insured sample and 20% in the Medicaid sample and probable misuse at 6% in commercially insured and at 3% in Medicaid. Among non-modifiable factors, younger age, back pain, multiple pain complaints and substance abuse disorders identify patients at high risk for misuse. Among modifiable factors, treatment with high daily dose opioids (especially >120 mg MED per day) and short-acting Schedule II opioids appears to increase the risk of misuse. The consistency of the findings across diverse patient populations and the varying levels of misuse suggest that these results will generalize broadly, but await confirmation in other studies. Ó
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Introduction
The use of chronic opioid therapy (COT) for chronic non-cancer pain (CNCP) has increased dramatically in the past two decades [13, 28] . There has also been a marked increase in the abuse of prescribed opioids [9, 13] . Indeed, in the U.S. prescription opioid abuse is the fastest growing form of drug abuse [9] and prescription opioids the most common cause of accidental drug overdose [24] . Misuse of prescribed opioids, defined by the National Institute of Drug Abuse as ''taking a medication in a manner other than that prescribed or for a different condition than that for which the medication is prescribed", [20] may contribute to these negative outcomes. Misuse may be a sign of developing or established opioid abuse. Misuse is also thought to contribute to the risk of accidental overdose [10] .
Results from the population-based U.S. National Survey on Drug Use and Health (NSDUH) from 2002 to 2005 show that 4.8% of the population over age 12 has used prescription pain reliever nonmedically in the previous 12 months [3] . These surveys provide estimates of non-prescribed use of opioids, but do not show its relationship to the use of COT for CNCP. Clinical surveys of patients on COT have provided widely varying (3-62%) estimates of the prevalence of opioid misuse according to a recent review. This review concluded that ''the psychometric properties of the published questionnaires and interview protocols are weak; moreover, the samples included in the studies are often small and unrepresentative" [29] . It is also not clear whether these surveys are valid or generalizable to the entire population of patients on COT.
Opioid misuse can be understood as part of a set of aberrant drug-related behaviors [26] . A recent review of evidence on aber- 
